Abivax SA American Depositary Shares

Yahoo Finance • yesterday

Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) Meeting

Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) Meeting Late Breaking Abstract titled EFFICACY OF OBEFAZIMOD IN ABTECT PHASE 3... Full story

Yahoo Finance • 11 days ago

SA Asks: Which biotechs could be acquired by year's end?

[word m and a made with wood building blocks, stock image] Maksim Labkouski The fourth quarter has historically been a busy time for the biopharma industry, with the sector generally seeing a significant uptick in M&A activity. We asked... Full story

Yahoo Finance • 12 days ago

Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review

Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review PARIS, France, September 12, 2025, 5:45 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX) (“Abivax” or the “Company”), a clinic... Full story

Yahoo Finance • 16 days ago

Abivax Presents First Half 2025 Financial Results

Abivax Presents First Half 2025 Financial Results PARIS, France, September 8, 2025, 10:00 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focu... Full story

Yahoo Finance • 19 days ago

Abivax jumps amid takeover speculation

[Torn pieces of paper with the words Ulcerative Colitis] Professor25/iStock via Getty Images Abivax (NASDAQ:ABVX [https://seekingalpha.com/symbol/ABVX]) shares rose 6.9% in Paris amid takeover speculation. Abivax ADRs gained 6%. There's... Full story

Yahoo Finance • 24 days ago

Abivax’s 580% surge hands biotech hedge funds a rare 2025 win

[Scientist taking a sample out of a petri dish using a pipette] DNY59/E+ via Getty Images Hedge funds specializing in biotech finally caught a break this summer, courtesy of a little-watched French drug developer, The Wall Street Journal... Full story

Yahoo Finance • 2 months ago

Abivax Announces Closing of $747.5 Million Public Offering

Abivax Announces Closing of $747.5 Million Public Offering PARIS, France, July 28, 2025 – 10:15 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on d... Full story

Yahoo Finance • 2 months ago

Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)

Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M) PARIS, France, July 25, 2025 – 08:00 a.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX... Full story

Yahoo Finance • 2 months ago

Abivax launches $400M ADS offering

* Abivax (NASDAQ:ABVX [https://seekingalpha.com/symbol/ABVX]) has launched a public offering [https://seekingalpha.com/filing/10215163]of American Depositary Shares (ADSs) in the U.S. to raise approximately $400 million (€340 million).... Full story

Yahoo Finance • 2 months ago

Piper Sandler raises Abivax stock price target to $70 on positive UC trial data

Investing.com - Piper Sandler raised its price target on Abivax (NASDAQ:ABVX) to $70.00 from $42.00 on Wednesday, while maintaining an Overweight rating following positive clinical trial results. According to InvestingPro data, analyst tar... Full story

Yahoo Finance • 2 months ago

Abivax Hits The Stratosphere, Up 500%, On 'Potentially Disruptive' Results

Shares of Abivax hit the stratosphere Wednesday after the firm unveiled "potentially disruptive" results for its ulcerative colitis drug. Continue Reading View Comments... Full story

Yahoo Finance • 2 months ago

Abivax's ulcerative colitis drug meets primary goals in Phase 3 trials; shares jump 400%

Investing.com -- Abivax shares rose over 400% in Paris on Wednesday after the French biotech company announced that its lead drug candidate obefazimod achieved primary endpoints in two Phase 3 clinical trials for ulcerative colitis. Accor... Full story

Yahoo Finance • 2 months ago

Abivax skyrockets 400% as late-stage trial for lead asset succeeds in ulcerative colitis

[Torn pieces of paper with the words Ulcerative Colitis] Professor25 Shares of Abivax (NASDAQ:ABVX [https://seekingalpha.com/symbol/ABVX]) rose over 400% in Paris on Wednesday after the French biotech announced that its lead asset, obefaz... Full story

Yahoo Finance • 2 months ago

Abivax Reports Strong Ulcerative Colitis Data; All Eyes On Next Catalyst, Stock Up Over 400%

(RTTNews) - Abivax SA (ABVX) has announced positive topline results from its phase III induction trials of its investigational drug Obefazimod in adult patients with moderately to severely active ulcerative colitis, sending its shares surg... Full story

Yahoo Finance • 2 months ago

Abivax stock price target raised to $95 from $33 at JMP on strong trial data

Investing.com - JMP Securities raised its price target on Abivax (NASDAQ:ABVX) to $95.00 from $33.00 on Wednesday, while maintaining a Market Outperform rating following positive Phase 3 trial results for the company’s ulcerative colitis t... Full story

Yahoo Finance • 2 months ago

US-listed Abivax shares skyrocket on positive phase 3 data for colitis drug

Investing.com-- U.S.-listed shares of French biotech firm Abivax SA (EPA:ABVX) (NASDAQ:ABVX) skyrocketed in post-market trading on Tuesday after the company reported strong results from late-stage trials of its oral ulcerative colitis tr... Full story

Yahoo Finance • 2 months ago

Abivax stock rating reiterated at Market Outperform by Citizens JMP

Investing.com - Citizens JMP analyst reiterated a Market Outperform rating and $33.00 price target on Abivax (NASDAQ:ABVX), a $641.2 million market cap biotech company, following a key opinion leader call that reinforced confidence in the... Full story

Yahoo Finance • 2 months ago

Citizens JMP reiterates Market Outperform rating on Abivax stock

Investing.com - Citizens JMP has reiterated its Market Outperform rating and $33.00 price target on Abivax (NASDAQ:ABVX) ahead of upcoming clinical trial results. The target represents a significant premium to the current stock price of $8... Full story

Yahoo Finance • 4 months ago

Earnings week ahead: NIO, LULU, AVGO, DOCU, CRWD, MDB, FCEL, DG, DLTR, HPE, and more

[Quarterly report concept.Company financial report.Business charts. Colorful quarter wooden pie chart pieces. Banner with copy space.] Mohamad Faizal Bin Ramli Despite a relatively sparse earnings calendar, the first full week of June fea... Full story